Unit:
Κατεύθυνση Αρτηριακή Υπέρταση και Συνοδά Καρδιαγγειακά-Νεφρικά ΝοσήματαLibrary of the School of Health Sciences
Author:
Kounatidis Dimitrios
Supervisors info:
Ιορδάνης Μουρούζης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Τσιούφης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ελευθέριος Τσιάμης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Η θέση των αναστολέων SGLT σε ασθενείς με καρδιακή ανεπάρκεια: Χορήγηση σε μη διαβητικούς ασθενείς
Translated title:
SGLT inhibitors in patients with heart failure: Administration in non diabetic patients
Summary:
Heart failure is a multifactorial and heterogeneous clinical syndrome, which affects about 64 million people worldwide. It is classified as heart failure with reduced (HFrEF), intermediate and preserved (HFpEF) ejection fraction respectively. The pathophysiological background seems to be different between HFrEF and HFpEF and as a consequence both diagnosis and treatment differ significantly. Despite progress in treatment, the prognosis continues to be poor, which makes it necessary to discover new drugs, which will contribute to the improvement of the symptoms with a simultaneous increase in survival. SLGT-2 inhibitors are a new class of antidiabetic drugs, with a unique mechanism of action, as they act through inhibition of glucose reabsorption in the proximal renal tube, causing glycosuria. They demonstrate pleiotropic effects, a fact that was the springboard to their use in heart failure. Results of multiple large studies showed the beneficial effect of these drugs in patients with heart failure with reduced ejection fraction (HFrEF), even in patients without diabetes mellitus. Multiple mechanisms have been proposed in an attempt to explain the protective effects of SGLT inhibitors on the heart and kidney, although it remains unclear how these drugs present these significant results. In any case, SGLT inhibitors seem to be a promising treatment in heart failure, expanding the therapeutic quiver in these patients.
Main subject category:
Health Sciences
Keywords:
Heart failure, SGLT inhibitors
Number of references:
130
File:
File access is restricted only to the intranet of UoA.
ΔΙΠΛΩΜΑΤΙΚΗ ΜΕΤΑΠΤΥΧΙΑΚΟΥ.pdf
2 MB
File access is restricted only to the intranet of UoA.
